Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TQB2618 Monotherapy and Combination in Advanced Colorectal Cancer
NCT06010901Phase 1Unknown
- Sponsor
- Chia Tai-Tianqing Pharmaceutical Group
- Start
- Jan 2024
- Primary completion
- Mar 2025
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of TQB2618 in colorectal cancer (CRC) (3 arms), sponsored by Chia Tai-Tianqing Pharmaceutical Group. Primary endpoint: Objective Response Rate up to 8 months. Status: unknown.
02
Drugs
TQB2618
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on NCT06010901.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06010901.